Opendata, web and dolomites

LIPOBITS SIGNED

Liposome-based Biomimetic Treatment for auto-immune diabetes (T1D)

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 LIPOBITS project word cloud

Explore the words cloud of the LIPOBITS project. It provides you a very rough idea of what is the project "LIPOBITS" about.

tolerance    diseases    competitors    chronic    considering    immunosuppressive    producing    onset    innovative    global    incidence    incomes    none    stopping    liposome    quality    insulins    worldwide    autoantigens    systemic    10    cure    scaling    start    containing    diabetes    treatments    permanent    lasting    ad    population    lower    reverse    vaccine    steady    immune    insulin    treatment    recover    antigen    effect    validated    qualified    total    company    biomimetic    auto    market    solid    t1d    secondary    cycle    2022    continuous    prevent    autoimmune    platform    network    roadmap    palliative    mainly    assays    cells    licensees    despite    ipr    regulatory    exogenous    jobs    liposomes    solution    feasibility    beta    preclinical    proprietary    society    advantages    generate    administration    models    therapeutic    ing    action    preventive    lipobits    asset    innovation    encapsulation    therapies    therapeutics    deeper    life    toxicity    induce    300    glycaemic    dimension    physiologic    animal    lt    detected    foreseen    complementary    acute    competitive    marketed    disease    sustained    discover    ahead    strategy    enlarging    mechanism    reaction   

Project "LIPOBITS" data sheet

The following table provides information about the project.

Coordinator
AHEAD THERAPEUTICS SL 

Organization address
address: EDIFICI EUREKA PARC RECERCA UAB CAMPUS UAB S/N
city: CERDANYOLA DEL VALLES
postcode: 8193
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.aheadtherapeutics.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2019-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AHEAD THERAPEUTICS SL ES (CERDANYOLA DEL VALLES) coordinator 50˙000.00

Map

 Project objective

Autoimmune diseases (AD) affect 5-10% of the global population and require chronic palliative treatments, resulting in lower quality of life and great costs for society. Moreover, a steady rise in the incidence of some AD such as Type 1 diabetes (T1D) has been detected worldwide. Main treatments for T1D are currently based on the continuous administration of exogenous insulin, but none of the 20 existing marketed insulins can achieve a sustained glycaemic level control. Thus, they cannot fully prevent T1D’s long term and acute side effects.

Ahead Therapeutics is a start-up company exploiting a proprietary encapsulation technology to develop treatments for different AD. It has developed an innovative solution for T1D based on the use of liposomes containing auto-autoantigens. Through a biomimetic process, these liposomes can induce antigen specific immune tolerance, stopping the autoimmune reaction and allowing insulin-producing β-cells to recover. Despite its potential for preventive use, Ahead’s treatment is mainly foreseen as a therapeutic reverse vaccine on the onset of T1D, leading to a permanent cure of the disease.

Ahead solution has several competitive advantages derived from its biomimetic/physiologic mechanism of action: long-lasting/permanent effect, non-systemic immunosuppressive, no secondary effects/toxicity, low-cost production, complementary with other therapies. The liposome-based platform has already been validated in animal models and preclinical non-regulatory assays are being completed. Current feasibility study will be now focus on defining a Regulatory Roadmap & IPR strategy, enlarging key partners network, discover new potential licensees, scaling up liposomes production and analyse deeper market & competitors.

LIPOBITS is a solid high-potential innovation project expected to support Ahead’s global dimension and to generate 7 high qualified jobs total incomes of 10,5 M€ by 2022, and < 300 M € considering the whole life cycle of the asset.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LIPOBITS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LIPOBITS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

PrasinoMed (2018)

First in the world ecological and sustainable cream for wound care, based on microalgaprasinococcus capsulatus

Read More  

GREEN WHS (2019)

NATURE FRIENDLY WATER HYDRAULIC STEERING SYSTEM

Read More  

TuneFork (2018)

Mobile technology that brings personalized audio into your life

Read More